BIO International 2025: Stifel's Tim Opler comments on improvements in sentiment he is seeing for the biotech sector, and his take on hot button issues

He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors. Plus, his take on the potential most favored nation policy, companies with negative enterprise values, and China competition.